Glaukos Corporation (GKOS)

Market Cap	6.68B +17.3%
Revenue (ttm)	507.44M +32.3%
Net Income	-187.69M
EPS	-3.28
Shares Out	58.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	707,039
Open	115.01
Previous Close	116.69
Day's Range	113.26 - 117.47
52-Week Range	73.16 - 130.23
Beta	0.78
Analysts	Strong Buy
Price Target	133.07 (+15.65%)
Earnings Date	Apr 29, 2026

About GKOS

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 1,094
• Stock Exchange: NYSE
• Ticker Symbol: GKOS
• Website: https://www.glaukos.com

Financial Performance

In 2025, Glaukos's revenue was $507.44 million, an increase of 32.33% compared to the previous year's $383.48 million. Losses were -$187.69 million, 28.2% more than in 2024.

Analyst Summary

According to 14 analysts, the average rating for GKOS stock is "Strong Buy." The 12-month stock price target is $133.07, which is an increase of 15.65% from the latest price.

Price Target

$133.07

(15.65% upside)

Analyst Consensus: Strong Buy